Asia-Pacific Osteoarthritis Therapeutics Market was valued at USD 7,500 million in 2021. It is expected to reach a value of USD 11,900 million by 2028, growing at a CAGR of 8.0% from 2022 to 2028. The market provides a detailed overview of the Asia-Pacific Osteoarthritis Therapeutics Market, which has been segmented by disease type, drug class, route of administration, and distribution channel. The market has been segmented by disease type into Ankle Osteoarthritis, Hip Osteoarthritis, Knee Osteoarthritis, Shoulder Osteoarthritis, and Others. The Knee Osteoarthritis segment is likely the most significant and fastest-growing segment in various disease types. The market has been segmented by drug class into Viscosupplementation Agents, NSAIDs, Analgesics, Corticosteroids, and Others. The Viscosupplementation Agents segment is expected to gain the maximum revenue share in the market over the forecast period 2022-2028. By route of administration, the Asia-Pacific osteoarthritis therapeutics market has been segmented into Oral, Topical, and Parenteral. The Parenteral segment accounted for the maximum revenue share. Based on the distribution channel, the Asia-Pacific Osteoarthritis Therapeutics is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. According to precision business insights, the Hospital Pharmacies segment is predicted to register the fastest growth rate during the forecast period.
In August 2020, Dr. Reddy’s Laboratories launched an over-the-counter Diclofenac Sodium topical gel used to treat arthritis pain in the US market.